U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07583654) titled 'Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors' on April 30.
Brief Summary: The goal of this phase 1 clinical trial is to evaluate the safety, tolerability, and preliminary antitumor activity of a peptide-delivered IL-22BP biotherapy in patients with advanced solid tumors. The main questions it aims to answer are:
Is the IL-22BP formulation safe and tolerable? Does the IL-22BP formulation show preliminary antitumor activity?
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
mRNA Vaccine
Solid Tumor Cancer
Peptides
Cancer Metastatic
Intervention:
BI...